Semorinemab in Mild-to-Moderate Alzheimer Disease

As antiamyloid beta antibodies continue to hit their target and regulatory approvals become a reality,1-3 targeting tau pathology represents the next frontier for Alzheimer disease prevention and treatment. In Alzheimer disease, tau tangle burden is more closely related to the onset and progression of cognitive decline than is amyloid beta plaque. Tau aggregates also drive many other forms of dementia making them a promising target of treatment on many fronts.